anti-vegf agents for the treatment of pigment epithelial detachments associated with neovascular age-related macular degeneration: an evidence-based approach
نویسندگان
چکیده
editorial, no abstract
منابع مشابه
Anti-VEGF Agents for the Treatment of Pigment Epithelial Detachments Associated with Neovascular Age-related Macular Degeneration: An Evidence-based Approach
Pegaptanib (Eyetech Pharmaceuticals and Pfizer), which was approved by the FDA at the end of 2004, was the first anti-VEGF therapy for neovascular AMD (3). After approval of bevacizumab (Genentech/ Roche) for cancer therapy and in view of the suspected role of VEGF in wet AMD, systemic intravenous and, later, intravitreal bevacizumab began to be administered off-label to treat neovascular AMD (...
متن کاملTreatment of Neovascular Age Related Macular Degeneration Associated with Pigment Epithelial Detachment: An Update
Ali Dirani1* and Ghassan Cordahi1 1Department of Ophthalmology, University of Montreal, Montreal, Quebec, Canada Retinal pigment epithelial detachment (PED) is defined as an anatomical separation of the retinal pigment epithelium (RPE) from the underlying Bruch layer [1]. Serous and vascularized (fibrovascular) PED are commonly present in eyes with neovascular AMD. According to some studies, up...
متن کاملVEGF polymorphisms are associated with neovascular age-related macular degeneration.
Age-related macular degeneration (AMD) is the most common cause of blindness in the elderly. Linkage has been shown to the vascular endothelial growth factor (VEGF) gene and ocular levels of VEGF are raised in individuals with the neovascular form of disease. To examine the role of VEGF further, we conducted a case-control study where 45 individuals with neovascular AMD and 94 age-matched contr...
متن کاملA Systematic Review of the Treat and Extend Treatment Regimen with Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
Despite significant progress in retaining vision for neovascular age-related macular degeneration patients in the era of treatment with intravitreal anti-VEGF agents, there is no universally accepted treatment regimen that defines the frequency of treatment needed to achieve the optimal visual outcomes while simultaneously balancing the burden of long-term, frequent and high-cost treatment. Tre...
متن کاملTreatment of Neovascular Age-Related Macular Degeneration with Anti-VEGF Agents: Predictive Factors of Long-Term Visual Outcomes
PURPOSE To evaluate the predictive factors of long-term visual outcomes in neovascular age-related macular degeneration (nAMD) treated with antivascular endothelial growth factor (anti-VEGF) agents. METHODS Unicentric retrospective review of patients with nAMD treated with anti-VEGF agents. Visual outcomes, 12 and 60 months after diagnosis, were evaluated. In an attempt to identify predictive...
متن کاملTreatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes
PURPOSE To evaluate the 5-year results obtained in clinical practice in the treatment of neovascular age-related macular degeneration (nAMD) with anti-VEGF agents. MATERIALS AND METHODS We retrospectively analyzed all patients with nAMD who initiated anti-VEGF treatment before October 2009. We collected data regarding visual and anatomical outcomes. RESULTS A total of 278 patients met the s...
متن کاملمنابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
medical hypothesis, discovery and innovation ophthalmology journalجلد ۴، شماره ۴، صفحات ۰-۰
میزبانی شده توسط پلتفرم ابری doprax.com
copyright © 2015-2023